Eudaimonia Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Eudaimonia Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-222	Closed	-$30K	–	1381
2021 Q1	$30K	Hold	222	–	–	0.01%	814
2020 Q4	$31K	Hold	222	–	–	0.01%	755
2020 Q3	$25K	Buy	+222	New	+$24.9K	0.01%	747

Other funds holding XBI

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Eudaimonia Partners's XBI Position: Q2 2021 in Review

Eudaimonia Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2021, closing a stake of 222 shares — an estimated $30K sold.

Eudaimonia Partners first reported a position in XBI in Q3 2020 and held it in 3 quarters. The position peaked at $31K in Q4 2020. 663 funds tracked by Wall St. Rank hold XBI as of Q2 2021.

Eudaimonia Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2021 after selling out during the quarter.
Eudaimonia Partners sold 222 State Street SPDR S&P Biotech ETF shares in Q2 2021, an estimated $30K.
Eudaimonia Partners first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and held it in 3 quarters.
Eudaimonia Partners's State Street SPDR S&P Biotech ETF position peaked at $31K in Q4 2020.
663 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.